The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback